Hikma Pharmaceuticals PLC
LSE:HIK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 722
2 083
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC
Total Current Liabilities
Hikma Pharmaceuticals PLC
Total Current Liabilities Peer Comparison
GSK
AZN
VRNA
INDV
DPH
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Total Current Liabilities
$1.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
1%
|
CAGR 10-Years
9%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Total Current Liabilities
£20.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
5%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Total Current Liabilities
$28.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Total Current Liabilities
$28m
|
CAGR 3-Years
0%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Total Current Liabilities
$1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Total Current Liabilities
£164m
|
CAGR 3-Years
6%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
See Also
What is Hikma Pharmaceuticals PLC's Total Current Liabilities?
Total Current Liabilities
1.4B
USD
Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Total Current Liabilities amounts to 1.4B USD.
What is Hikma Pharmaceuticals PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
9%
Over the last year, the Total Current Liabilities growth was 14%. The average annual Total Current Liabilities growth rates for Hikma Pharmaceuticals PLC have been 13% over the past three years , 1% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet
